BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsUpgradesPrice Target
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.